Semaglutide 5mg

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1) with 94% homology to native human GLP-1. This 31-amino-acid peptide (MW: 4113.58 Da) incorporates strategic modifications that extend its half-life:

Structural Modifications:

Substitution of Alanine by 2-aminoisobutyric acid (AIB) at position 8
Acylation at Lysine-26 with a C18 fatty acid via a spacer
A hydrophobic side chain that facilitates binding to serum albumin (>99%)

Molecular Mechanisms:

• GLP-1R receptor: Selective activation in pancreatic β-cells, hypothalamus, and gastrointestinal tract
  cAMP/PKA pathway: Increase in intracellular cyclic AMP → glucose-dependent insulin secretion
• Glucagon Suppression: Pancreatic alpha-cell inhibition during hyperglycemia
  Gastric Emptying: Delay Mediated by Vagal Signaling (70% Reduction)
• Central Satiety Activation of POMC/CART neurons in the hypothalamic arcuate nucleus

Advanced Pharmacokinetics:

• Subcutaneous bioavailability: 89%
• Tmáx: 1-3 days post-injection
• Median life 165-184 hours (weekly administration)
• Renal clearance: <1% (primary proteolytic degradation)
• Steady state: 4-5 weeks

Metabolic Regulation in Experimental Models
Glycemic Control

• HbA1c reduction: 1.5–2.01 TP3T in diabetic models (Aroda et al., 2017)
• Increased insulin secretion: 200-300% during oral tolerance testing
• Improves insulin sensitivity: Reduced HOMA-IR index 40-50%

Body Weight Modulation:

• Weight reduction: 12-15% in long-term studies (68 weeks) (Wilding et al., 2021)
• Visceral fat loss: 25-30% above the subcutaneous tissue
• Lean mass preservation: A loss of 85-90% corresponds to adipose tissue

Cardiovascular Effects (SUSTAIN Studies):

• Reduction of MACE events: 26% vs. placebo (Marso et al., 2016)
• Decrease in systolic blood pressure: 4-6 mmHg
• Improves lipid profile: triglyceride reduction 15-20%

Neuroprotection and Cognitive Function

Neurodegeneration Models:

• Reduction of beta-amyloid plaques in Alzheimer's models: 30-40% (Cai et al., 2018)
• Prevention of dopaminergic neuronal loss in Parkinson's
• Attenuation of neuroinflammation: decrease in IL-6, TNF-α (50–60%)

Synaptic Plasticity:

• Increase in BDNF (Brain-Derived Neurotrophic Factor): 25-35%
• Improved hippocampal long-term potentiation (LTP)
• Neurogenesis in the dentate gyrus: increase 40%

Dosing in Animal Models

In Vitro Studies

Cell Cultures:

• Pancreatic β cells (INS-1): 1-100 nM in complete medium.
• Primary neurons: 10-50 nM with 48-72h exposure.
• 3T3-L1 adipocytes 5-25 nM during differentiation.

Standard Protocol:

1. Use sterile bacteriostatic water (pH 7.0-7.4)
2. For 5mg vial: add 2.0mL → concentration 2.5mg/mL
3. Inject slowly down the vial wall (avoid foaming)
4. Gently roll for 30-60 seconds (DO NOT shake vigorously)
5. Check for clear, particle-free solution

Post-Reconstitution Storage:

• Refrigeration: 2-8°C for up to 56 days
• Protect from direct light (amber vials recommended)
• Prevent complete freezing (<-20°C)
• Allow to reach room temperature before administration

Q: How does Semaglutide compare to other GLP-1 agonists? R: It presents a higher affinity for GLP-1R (EC50: 0.38 nM vs 1-5 nM for liraglutide) and a 7-fold longer half-life, allowing for weekly administration versus daily.

P: Is it compatible for research in combination with insulin? A: Yes, studies show a synergistic effect on glycemic control with a 30% reduction in the required insulin dose (Aroda et al., 2017).

Q: What biochemical markers should be monitored in prolonged studies? R: Plasma glucose, HbA1c, C-peptide, glucagon, serum lipase, renal function (creatinine, BUN), and inflammatory markers (CRP, IL-6).

P: What is the optimal timing for metabolic evaluations? R: Steady state reached in 4-5 weeks; continuous glycemic measurements require at least 8 weeks for full effects.

1. Aroda VR, et al. (2017) “Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine” – Lancet Diabetes Endocrinol 5(5):355-366. [PubMed: 28344112]
2. Wilding JPH, et al. (2021) “Once-Weekly Semaglutide in Adults with Overweight or Obesity” - The New England Journal of Medicine384(11):989-1002. [PubMed: 33567185]
3. Marso SP, et al. (2016) “Semaglutide and Cardiovascular Outcomes in Diabetes” – The New England Journal of Medicine 375(19):1834-1844. [PubMed: 27633186]
4. Cai HY, et al. (2018) “GLP-1 treatment protects Alzheimer model through enhancing neuronal insulin signaling” – Brain Res 1678:64-72. [PubMed: 29128461]
5. Novo Nordisk Research (2017) “Pharmacokinetic properties of semaglutide” – Diabetes Obes Metab 19(1):140-147.

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.